A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
EGFR and COX-2 are involved in tumorigenesis, angiogenesis and metastases and are frequently
over expressed in NPC.COX-2 and EGFR inhibitors are active in NPC.There is synergistic action
between COX-2 and EGFR inhibitors.
Study hypothesis: Celecoxib and gefitinib can reduce angiogenesis and induce
anti-tumorigenicity in patients with nasopharngeal cancer.